Followers | 261 |
Posts | 19732 |
Boards Moderated | 0 |
Alias Born | 10/03/2004 |
![](https://investorshub.advfn.com/uicon/45965.png?cb=1637315758)
Monday, September 17, 2007 10:35:01 AM
Here is the PR from last year:
http://findarticles.com/p/articles/mi_m0EIN/is_2006_Nov_27/ai_n16867506
NanoViricides Reports at NanoBiotech 2006 Conference: AviFluCide-I™ and FluCide-I™ Best Drugs against H5N1 and Common Influenzas, Respectively
Business Wire, Nov 27, 2006
WEST HAVEN, Conn. -- NanoViricides, Inc., (Pink Sheets: NNVC)
Dr. Anil Diwan, Company President and Chairman, provided a synthesis of the results so far obtained against common influenza (H1N1) animal studies and avian flu (H5N1) cell culture studies at the NanoBiotech 2006 Conference in Boston on November 17th.
"We can extrapolate that AviFluCide could be between 40 times (4,000%) to 200 times (20,000%) superior to Tamiflu in H5N1 field events," said Dr. Diwan, explaining this with scientific data, "We know that AviFluCide-I was almost 4 times superior to FluCide against H5N1, and that FluCide was almost 10 times (1000%) superior to Oseltamivir (Tamiflu(R) Roche) in animal studies. Further, Tamiflu efficacy against H5N1 may be as low as 1/10th its efficacy against common influenza, as suggested by several international studies in mice as well as scant clinical data from human treatment."
"Our upcoming H5N1 animal studies in Vietnam should provide significant important data. Often, the simple mathematical relationships are not upheld in animal studies because the biological systems are very complex," said Dr. Krishna Menon, Chief Regulatory Officer, who conducted the animal studies. He further added, "Nevertheless, it is quite clear that these nanoviricides appear to be currently the best drugs available against influenzas including avian flu."
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM